Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 6/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25237253 | 1.00 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL29528156 | 1.00 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL5988009 | 1.00 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL29602919 | 0.98 | HTR1B (0.65) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL5988043 | 0.98 | HTR1B (0.65) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL31079904 | 0.86 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL25172149 | 0.86 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL31079721 | 0.86 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL29366170 | 0.86 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL5987271 | 0.86 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124101-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11534454-B2 | Complexing agent salt formulations of pharmaceutical compounds | BEXSON BIOMEDICAL, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220152088-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152088-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC10A1, SLC5A6, MC2R | HTR1B 2136/4885HTR2A 2775/4885HTR2C 2307/4885 |
| US-11534454-B2 | Complexing agent salt formulations of pharmaceutical compounds | SLC10A1, SLC5A6, MC2R | HTR1B 2136/4885HTR2A 2775/4885HTR2C 2307/4885 |
| US-20230124101-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC10A1, SLC5A6, MC2R | HTR1B 2136/4885HTR2A 2775/4885HTR2C 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.